Erica L. Schwarz, Ph.D.

Predictive Modeling and Clinical Translation

I collaborate extensively with multi-institutional teams of clinicians and researchers to advance the development of tissue-engineered vascular grafts, using computational models of vascular behavior to predict surgical outcomes and define safety limits for cardiovascular function. These computational tools directly accelerate the clinical translation of new medical technologies.

Research Pathway

In 2012, the first U.S. clinical trial of tissue-engineered vascular grafts (TEVGs) began at Nationwide Children’s Hospital in Columbus, Ohio. Previous studies in Japan had shown the efficacy of TEVGs to replace the synthetic grafts traditionally used in patients undergoing the Fontan procedure. However, upon imaging the first four patients in the U.S. trial 6 months post-operation, clinicians narrowing (a.k.a. stenosis) in the grafts. The clinical trial was paused to answer the questions “how does narrowing of TEVGs impact cardiovascular health?” and “what biomechanical factors drive the narrowing of TEVGs?”. To answer these questions, I created novel models of the post-operational Fontan cardiovascular system, including new quantification of pediatric exercise in single-ventricle patients and a fluid-structure-growth multiphysics solver capable of simulating changes in growth and remodeling in response to hemodynamic factors. These insights contributed to the renewal of the clinical trial, showing the ability of computational models to advance the adoption of medical technologies.

My work in clinical translation of computational models has continued and expanded to include investigations of aortic aneurysms, cerebral aneurysms, and cardiovascular devices.

Selected Publications